Ascentage Pharma Shares Surge 6.53% on Strong Clinical Pipeline & Global Strategy
Ascentage Pharma Group sees a 6.53% rally, driven by a strong clinical pipeline, global reach, and attractive valuation below its all‑time high.
3 minutes to read
ASCENTAGE PHARMA GR
Ascentage Pharma’s Breakthrough Designation for Lisaftoclax Spurs Market Shift
Ascentage Pharma’s Lisaftoclax earns Breakthrough Therapy status, sparking a sharp market dip—learn why investors watch this biotech move.
3 minutes to read
Ascentage Pharma Shares Rise 2.3% as Breakthrough Therapy Designation Boosts Growth
Ascentage Pharma rises on Breakthrough Therapy news for lisaftoclax/acalabrutinib combo, boosting its market cap and CLL treatment prospects.
3 minutes to read
Ascentage Pharma (6855.HK) Gains 2.76% – Latest Trading & Market Metrics
Ascentage Pharma Group (6855.HK) surged 2.76% to HK$31.26, rising above its 200‑day SMA while peers stayed flat. Learn why biotech investor interest is growing.
2 minutes to read